Xeris reports higher revenue and wider quarterly loss
Xeris Biopharma Q2 2026 revenue rose 29% year over year to $92.1 million; net product revenue climbed 34% to $91 million.
GAAP net loss widened to $31.1 million, due to a one-time, non-cash charge of about $31 million tied to 2028 Convertible Notes exchanges.
GAAP gross margin improved 4 percentage points to 86%.
Recorlev net revenue more than doubled, up 81% year over year to about $57 million.
Full-year 2026 revenue guidance was tightened to $385 million-$390 million; Keveyis patent allowance is expected to extend protection through at least 2039.
XERS•
